« back to reports
Medtech Report

Q3 2023

Medtech Report

November 28, 2023

Medtech deals surge into Q4 

Would you invest in a startup developing a cardiovascular surgical device? If yes, you’re not alone: It’s been the most active category for medtech investment in 2023 year to date, with $487.7 million in VC funding in Q3 alone. Cancer diagnostics and surgical robotics have also been locking up major dollars, according to our Q3 2023 Medtech Report.  

Leading the pack are names such as Neuralink and Beta Bionics, both of which closed nine-figure deals in late Q3, setting the stage for a strong finish for the year.  

Table of contents
Vertical update 3
Q3 2023 timeline 5
Medtech landscape 6
Medtech VC and PE ecosystem market map 7
VC and PE activity 9
Emerging opportunities 13
       Voice-based diagnostics 14
       Minimal residual disease 16
Select company highlights 18
       Beta Bionics 19
       Noah Medical 21
Appendix 23